2-Phenyl-4-[cis-2,5-dimethyl-4-(2-pyridinyl)-1-piperazinyl]quinazoline
AssigneeA. H. Robins Company, Incorporated
InventorYing-Ho Chen
Life of this patent
Estimating the term…
Abstract
Novel hypotensive agents are disclosed which are quinazolines substituted in the 2 and 4 position having the general formula: ##STR1## wherein Q is a secondary amine radical illustrated by loweralkanolylamino or a tertiary amine radical such as pyrrolidinyl, piperidinyl or piperazinyl, any of which may be substituted by various groups such as loweralkanolyl.
Claims14
The method of treating hypertension in warm blooded animals which comprises administering to said animal an effective amount of a compound having the formula:
- ##STR8## wherein Q is ##STR9## or --NR.sub.3 R.sub.4 R is selected from hydrogen, hydroxy, loweralkoxy, loweralkanolyl, phenoxy or phenoxy substituted by loweralkyl, loweralkoxy, trifluoromethyl, amino, nitro or halo;
- Z is selected from ##STR10## and p is zero to one inclusive;
- R.sub.1 is selected from loweralkyl, loweralkanolyl, 2-pyridyl, loweralkenyloxy-loweralkanolyl, loweralkynyloxyloweralkanolyl, loweralkanyloxy-loweralkanolyl, phenoxyloweralkanolyl and phenoxy-loweralkanolyl having phenoxy substituted by loweralkoxy, loweralkyl, nitro, amino, trifluoromethyl and halo;
- R.sub.2 is selected from hydrogen, hydroxy, loweralkyl, loweralkoxy, phenoxy or naphthoxy;
- R.sub.3 is selected from loweralkanolyl, 4-cyanocyclohexylloweralkyl, phenoxy-loweralkanolyl or phenoxy-loweralkanolyl having phenoxy substituted by loweralkoxy, loweralkyl, nitro, amino, trifluoromethyl or halo;
- R.sub.4 is selected from hydrogen or loweralkyl;
- X is selected from hydrogen, loweralkyl, loweralkoxy, nitro, amino or halo and n is one to three;
- Y is loweralkyl and m is 0 to 2 inclusive and the pharmaceutically acceptable addition salts and hydrates thereof.
A pharmaceutical composition for treating hypertension in warm-blooded animals for the purpose of lowering blood pressure comprising (a) an effective amount of a compound selected from the group consisting of 4-(4-hexyl-1-piperazinyl)-2-phenylquinazoline, 1-(2-phenyl-4-quinazolinyl)-3-piperidinemethanol, 4-[3-(2-methoxyphenoxyl-1-pyrrolidinyl]-2-phenylquinazoline, 2-phenyl-4-[4-(2-pyridinyl)-1-piperazinyl]quinazoline and 4-(2-phenyl-4-quinazolinyl-.alpha.-[(2-propenyloxy)methyl]-1-piperazineeth anol and (b) a pharmaceutically acceptable carrier therefor.
Dependencies are inferred from the claim text.